We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

27 hedge funds and large institutions have $7.68M invested in aTyr Pharma in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more capital invested

Capital invested by funds: $5.25M → $7.68M (+$2.43M)

0.35% more ownership

Funds ownership: 2.52% → 2.87% (+0.35%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

7% less funds holding

Funds holding: 29 → 27 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
27
Holders Change
-2
Holders Change %
-6.9%
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$929K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$720K
3
Renaissance Technologies
Renaissance Technologies
New York
+$87.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$25.2K
5
VF
Virtu Financial
New York
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$49K
2
Two Sigma Investments
Two Sigma Investments
New York
-$20.8K
3
Macquarie Group
Macquarie Group
Australia
-$9K
4
BlackRock
BlackRock
New York
-$1.78K
5
Morgan Stanley
Morgan Stanley
New York
-$235
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$2.38M – – –
Viking Global Investors
2
Viking Global Investors
Connecticut
$1.77M +$929K +130,404 +132%
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$1.01M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$960K +$720K +101,157 +430%
Renaissance Technologies
5
Renaissance Technologies
New York
$847K +$87.8K +12,329 +13%
BlackRock
6
BlackRock
New York
$101K -$1.78K -250 -2%
GHCM
7
Glen Harbor Capital Management
California
$84K – – –
MCIM
8
Meadow Creek Investment Management
Georgia
$69K – – –
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$67K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$58K – – –
EP
11
Elkfork Partners
Oregon
$55K – – –
BFM
12
Boothbay Fund Management
New York
$52K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$45K +$25.2K +3,534 +157%
RCM
14
Riverhead Capital Management
Delaware
$44K – – –
TAM
15
Tyers Asset Management
Texas
$40K – – –
Two Sigma Investments
16
Two Sigma Investments
New York
$37K -$20.8K -2,921 -38%
VF
17
Virtu Financial
New York
$23K +$21.1K +2,962 New
Northern Trust
18
Northern Trust
Illinois
$17K – – –
WS
19
Wedbush Securities
California
$14K +$13.2K +1,857 New
Two Sigma Advisers
20
Two Sigma Advisers
New York
$7K – – –
Bank of America
21
Bank of America
North Carolina
$4K – – –
RE
22
RBC Europe
United Kingdom
$3.3K – – –
Morgan Stanley
23
Morgan Stanley
New York
$2K -$235 -33 -12%
PAM
24
Panagora Asset Management
Massachusetts
$1K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
– -$49K -7,083 Closed
1
2

ATYR Hedge Fund Activity: Q1 2019 in Review

27 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2019, worth a combined $7.68M — up 46% from $5.25M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATYR and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Viking Global Investors, adding an estimated $929K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $49K sold.

  • 27 institutional investors held aTyr Pharma (ATYR) as of Q1 2019, down from 29 in Q4 2018.
  • Funds reported $7.68M of aTyr Pharma stock for Q1 2019, up 46% quarter-over-quarter.
  • 2 funds opened new aTyr Pharma positions in Q1 2019 and 4 closed out, a net change of -2 holders.
  • The largest aTyr Pharma buyer in Q1 2019 was Viking Global Investors, an estimated $929K added.
  • The largest aTyr Pharma seller in Q1 2019 was Susquehanna International Group, an estimated $49K sold.

Based on aggregated 13F filings for Q1 2019.